GLP-1 drugs like Ozempic have been hailed for their significant weight loss effects. However, recent research as of November ...

Patients with colon cancer using GLP-1 receptor agonists (the class of drugs behind treatments like Ozempic, Wegovy, and ...

GLP-1 receptor agonists improve glycaemic control and provide renal, metabolic, and selective cardiovascular benefits in people with type 2 diabetes, based on an umbrella review of 17 meta-analyses.

GLP-1 drugs like tirzepatide and semaglutide offer powerful weight-loss effects but come with unanswered questions about long ...

Patients with type 2 diabetes who use GLP-1 receptor agonists have a significantly lower risk for lung cancer than those who ...

A 14-study meta-analysis found GLP-1 receptor agonists -- especially semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, ...

A new University of California San Diego study offers compelling evidence that glucagon-like peptide-1 (GLP-1) receptor ...

Systematic review suggests GLP-1 receptor agonists offer strong preclinical neuroprotection in nondiabetic ischemic stroke, ...

For adults with type 2 diabetes and/or overweight/obesity and high triglycerides, GLP-1RAs are not associated with pancreatitis.

GLP-1RAs improved RA disease activity, pain scores, weight, cholesterol, and HbA1c levels in patients with a BMI ≥27. Nearly one-third of patients discontinued GLP-1RA therapy due to gastrointestinal ...

People taking GLP-1 medications had better-controlled asthma overall, though there was no difference in lung function compared to those not taking GLP-1s. The study suggests that GLP-1 drugs may have ...

The U.S. Food & Drug Administration (FDA) has approved certain GLP-1 drugs for commercialization and use, including liraglutide (Victoza®), semaglutide (Ozempic®, Wegovy®), and tirzepatide (Mounjaro®, ...